Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07829900) titled 'First-Line Dual Versus Single HER2-Targeted Therapy With Docetaxel for Advanced HER2-Positive Breast Cancer' on Sept. 14.

Study Type: Observational

Primary Sponsor: Xin Li

Condition: HER2-Positive Breast Cancer Advanced Breast Cancer

Intervention: Drug: Pertuzumab Drug: Trastuzumab

Recruitment Status: Not recruiting

Date of First Enrollment: April 20, 2020

Target Sample Size: 2250

Countries of Recruitment: China

To know more, visit https://clinicaltrials.gov/study/NCT07829900

Published by HT Digital Content Services with permission from Health Daily Digest....